What is the target price for Pro Medicus?
Institutional analyst consensus price targets for Pro Medicus Limited (ASX: PME) average approximately A$190.68, with high-end projections reaching up to A$250.00. Healthcare technology researchers highlight accelerating adoption of its Visage enterprise imaging software solutions across North American hospital networks, high operating profit margins, and recurring SaaS contract wins as primary drivers.
Related FAQs
Determining whether securities designated under the symbol PME are undervalued or overvalued involves conducting rigorous fundamental valuation analysis, including price-to-earnings evaluations, cash flow forecasting, and comparative industry benchma...
Assessing whether specific equities or investment funds trading under the ticker symbol PME represent sound long-term investments requires careful examination of underlying asset classes, management fee structures, and historical performance metrics.
The abbreviation PME can represent several distinct technical, medical, and financial terms depending on the professional context.
Market consensus recommendations for Pro Medicus (ASX: PME) generally span a mix of hold and buy ratings among healthcare technology equity researchers.
The abbreviation PME stands for several distinct concepts depending on the professional industry, most notably Public Market Equivalent in finance, which is a vital analytical tool used to compare private equity returns against public stock benchmark...
Entities operating under the ticker PME or specialized engineering and infrastructure designations navigate distinct competitive landscapes depending on their core industry focus.
Pro Medicus Limited shares trade actively on the Australian Securities Exchange under the ticker symbol PME, reflecting live market valuations driven by global demand for enterprise medical imaging software, radiology information systems, and Picture...
Progressive Bank operates as a regional financial institution providing community-focused banking services, establishing a distinct profile when evaluated against massive multi-state commercial banks and national financial conglomerates.
In corporate finance and alternative investment analysis, PME stands for Public Market Equivalent, which serves as a benchmark methodology used to evaluate the performance of private equity and venture capital funds against public market indexes.
Pro Medicus Limited is a prominent global healthcare technology and medical imaging software company specializing in enterprise-grade radiology information systems and Picture Archiving and Communication System solutions.
Pro Medicus Limited, a prominent global health imaging IT and software development company, officially completed its initial public offering and commenced trading its ordinary shares on the Australian Securities Exchange under the ticker symbol PME i...
Pro Medicus is firmly classified as a specialized healthcare technology stock rather than a traditional medical device manufacturer.
Premier investment and asset management strategies or specialized corporate frameworks associated with private market equity deliver distinct financial advantages for institutional and high-net-worth investors.
Progressive Bank provides digital banking solutions, mobile applications, and electronic funds transfer services to help personal and business customers manage their finances securely.
Pro Medicus Limited (PME) is a premier Australian health imaging IT software company providing sophisticated radiology picture archiving and communication systems (PACS) to major hospitals and healthcare networks internationally.
Pro Medicus Limited posted a record-breaking full-year financial performance, highlighting robust commercial growth across its global healthcare technology operations. The company reported an impressive net profit of $115.
Interest rates offered by the Bank of Herrin fluctuate according to designated deposit product classifications, compounding frequencies, and prevailing macroeconomic conditions governed by central bank policies.
As of July 2026, Procore Technologies (PCOR) has a market capitalization of approximately ₹598.48 billion.
Pro Medicus sells sophisticated healthcare information technology software and diagnostic imaging solutions, centered primarily around its flagship Practice Management and enterprise-grade Radiology Information System and Picture Archiving and Commun...
Wall Street equity research analysts assign consensus strong buy ratings to companies demonstrating exceptional pricing power, dominant market shares, and reliable double-digit earnings growth projections.
Pro Medicus Limited (ASX: PME) is widely recognized by healthcare technology equity analysts as a premier, highly profitable global medical imaging software enterprise.
Pro Medicus Limited (ASX: PME) is widely regarded by healthcare technology equity researchers as an exceptional long-term investment, driven by its scalable cloud-based Visage diagnostic imaging software and strong recurring revenue model.
Pro Medicus demonstrates robust, continuous financial and operational growth, driven by rapid international hospital network adoptions of its cloud-based diagnostic imaging platforms.
Equity research analysts evaluate Prime Infrastructure Capital and similarly designated enterprises (or entities trading under the ticker PME) with favorable long-term growth prospects, anchored by critical infrastructure investments, utility service...
Retail investors evaluating opportunities on the Australian Securities Exchange frequently examine major diversified mining conglomerates, leading commercial banking institutions, and prominent healthcare providers that anchor the domestic economy.